{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:14:06Z","timestamp":1785726846644,"version":"3.56.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Stevens\u2010Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe mucocutaneous adverse drug reactions associated with high morbidity and mortality. Current treatment regimens are largely supportive, and evidence for adjunctive systemic therapies remains limited. Recent research has implicated the Janus Kinase (JAK) signal transducer and activator of transcription (STAT) pathway in SJS\/TEN pathogenesis, raising interest in JAK inhibitors as potential targeted therapies. This scoping review aimed to evaluate the existing literature on the use of JAK inhibitors in the management of SJS\/TEN, summarise clinical outcomes and identify key research gaps. This scoping review was conducted in accordance with PRISMA\u2010ScR guidelines. A systematic search of Medline, Web of Science, Embase and Scopus was conducted from inception up to 12 June 2025. Nine studies were included, comprising eight case reports and one translational research study, reporting on 15 patients (median age 45\u2009years) treated with ruxolitinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097), tofacitinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095) or abrocitinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093). Most cases involved severe or treatment\u2010refractory disease. Among the eight cases where time to re\u2010epithelialisation was reported, six described 20%\u201330% re\u2010epithelialisation by day 7 and one described 95% re\u2010epithelialisation by day 16. No JAK inhibitor\u2010related adverse events were reported. Preclinical studies supported a mechanistic role for the JAK\/STAT pathway in keratinocyte apoptosis and inflammation. JAK inhibitors show promise as a novel therapeutic approach in SJS\/TEN; however, current evidence is limited by small sample sizes, disease severity, concomitant therapies and potential publication bias. Well\u2010designed prospective trials are needed to determine efficacy, safety and optimal use in this life\u2010threatening condition.\n                  <\/jats:p>","DOI":"10.1111\/ajd.70017","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:25:45Z","timestamp":1765952745000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evidence for the Use of Janus Kinase (\n                    <scp>JAK<\/scp>\n                    ) Inhibitors in the Management of Stevens\u2010Johnson Syndrome and Toxic Epidermal Necrolysis: A Scoping Review"],"prefix":"10.1111","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5118-9478","authenticated-orcid":false,"given":"Stephanie","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Dermatology Sir Charles Gairdner Hospital  Nedlands Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Bourke","sequence":"additional","affiliation":[{"name":"Department of Allergy and Immunology Fiona Stanley Hospital  Murdoch Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael S.","family":"Foster","sequence":"additional","affiliation":[{"name":"Department of Dermatology Sir Charles Gairdner Hospital  Nedlands Western Australia Australia"},{"name":"Department of Dermatology Fiona Stanley Hospital  Perth Western Australia Australia"},{"name":"Perth Children's Hospital  Perth Western Australia Australia"},{"name":"The Kids Research Institute  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Raby","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Fiona Stanley Fremantle Hospitals Group  Murdoch Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-040X","authenticated-orcid":false,"given":"Bernadette M.","family":"Ricciardo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fiona Stanley Hospital  Perth Western Australia Australia"},{"name":"Perth Children's Hospital  Perth Western Australia Australia"},{"name":"The Kids Research Institute  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-39"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1993.01680220104023"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.023"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13903"},{"issue":"9","key":"e_1_2_10_6_1","article-title":"A Review of the Systemic Treatment of Stevens\u2010Johnson Syndrome and Toxic Epidermal Necrolysis","volume":"10","author":"Chang H. C.","year":"2022","journal-title":"Biomedicine"},{"key":"e_1_2_10_7_1","article-title":"Systemic Interventions for Treatment of Stevens\u2010Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS\/TEN Overlap Syndrome","volume":"3","author":"Jacobsen A.","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16685"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08061-0"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.17605\/OSF.IO\/F5QBA"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0611-x"},{"key":"e_1_2_10_13_1","unstructured":"J.Lely H. C.Morris N.Sasson et\u00a0al. \u201cHow to Write a Scoping Review Protocol: Guidance and Template \u201d(2023) https:\/\/www.researchgate.net\/publication\/372412818_How_to_Write_a_Scoping_Review_Protocol_Guidance_and_Template."},{"issue":"6","key":"e_1_2_10_14_1","first-page":"368","article-title":"Graft\u2010Versus\u2010Host Disease Variety Toxic Epidermal Necrolysis. Case Report","volume":"81","author":"Z\u00fa\u00f1iga\u2010Lara E. M.","year":"2024","journal-title":"Bolet\u00edn M\u00e9dico del Hospital Infantil de M\u00e9xico"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.07.022"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107779"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.020"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1452245"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.10.004"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1089\/derm.2024.0229","article-title":"Tofacitinib as a Possible Treatment for Tacrolimus\u2010Induced Stevens\u2010Johnson Syndrome: A Case Report","volume":"36","author":"Li M.","year":"2024","journal-title":"Dermatitis"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.04.048"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414136"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611404094"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae321"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93349"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17860"},{"key":"e_1_2_10_27_1","unstructured":"\u201cAn Open\u2010Label Pilot Study to Evaluate the Safety Tolerability and Efficacy of Tofacitinib in Patients With Stevens\u2010Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)\u201d(2024) https:\/\/clinicaltrials.gov\/study\/NCT06474078."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S436637"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.70017","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:03:06Z","timestamp":1773043386000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.70017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/ajd.70017"],"URL":"https:\/\/doi.org\/10.1111\/ajd.70017","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"2025-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}